Potential Antitumor Activity of Combined Lycopene and Sorafenib against Solid Ehrlich Carcinoma via Targeting Autophagy and Apoptosis and Suppressing Proliferation

• Auteurs principaux: Thanaa A. El-Masry (Auteur), Maysa M. F. El-Nagar (Auteur), Nageh A. El Mahdy (Auteur), Fatemah A. Alherz (Auteur), Reham Taher (Auteur), Enass Y. Osman (Auteur)
• Format: Livre
• Publié: MDPI AG, 2024-04-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

An FDA-approved kinase inhibitor called sorafenib (SOR) is used to treat primary kidney and liver cancer as well as to stop the spread of advanced breast cancer. Side effects from SOR, such as palmar-plantar erythrodysesthesia syndrome, can negatively impact an individual's quality of life. The...